--- title: "Weight-Loss Pills vs Injections: Which?" description: "Neither route is automatically better. Compare approved weight-loss pills and injections by mechanism, daily routine, trial results and risks." summary: "Neither route is automatically better. In separate trials, oral semaglutide 25 mg averaged 13.6% loss at 64 weeks and the 2.4 mg weekly injection 14.9% at 68 weeks; the molecule, routine and your health history matter more." canonical: https://remevihealth.com/blog/weight-loss-pills-vs-injections/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "Linda West-Conforti, RN" reviewStatus: current reviewedDate: 2026-10-08T00:00:00.000Z pubDate: 2026-06-12T00:00:00.000Z updatedDate: 2026-09-14T00:00:00.000Z tags: ["weight-loss pills","weight-loss injections","oral semaglutide","GLP-1","prescription weight loss"] alternateLanguage: https://remevihealth.com/es/blog/pastillas-vs-inyecciones-para-bajar-de-peso/ license: "© 2026 REMEVi LLC. Please cite https://remevihealth.com/blog/weight-loss-pills-vs-injections/ as the source." --- ## Short answer Neither route is automatically better. In separate trials, oral semaglutide 25 mg averaged 13.6% loss at 64 weeks and the 2.4 mg weekly injection 14.9% at 68 weeks; the molecule, routine and your health history matter more. **Medically reviewed by** [Linda West-Conforti, RN](/medical-team/) · [CA RN #389453](https://search.dca.ca.gov/details/4500/RN/389453/) · 2026-10-08. Founding Nurse · Patient Care Lead. Neither route is automatically better: the molecule, approved use, risks and routine matter more than the route. In separate trials, oral semaglutide 25 mg averaged 13.6% weight loss at 64 weeks ([OASIS 4](https://doi.org/10.1056/NEJMoa2500969)) and weekly semaglutide 2.4 mg injections averaged 14.9% at 68 weeks ([STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/), NEJM 2021). Those are trial results, not REMEVi averages. ## Are weight-loss pills or injections more effective? **Quick answer:** Route alone cannot rank medicines. In trials, results differed by molecule, dose and population, and separate trials cannot be compared directly. Trials inform the studied product, dose and population. Comparing percentages across different trials does not establish treatment equivalence, and it does not establish that one route works better. Different populations, protocols and handling of missing data limit those comparisons. | Medicine and route | Trial | Average weight change in the trial | Placebo | |---|---|---|---| | Semaglutide 2.4 mg, weekly injection (Wegovy) | [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/), NEJM 2021, 68 weeks | −14.9% | −2.4% | | Tirzepatide 15 mg, weekly injection (Zepbound) | [SURMOUNT-1](https://pubmed.ncbi.nlm.nih.gov/35658024/), NEJM 2022, 72 weeks | −20.9% | −3.1% | | Oral semaglutide 25 mg, daily tablet (Wegovy tablets) | [OASIS 4](https://doi.org/10.1056/NEJMoa2500969), 64 weeks | −13.6% | −2.2% | | Orforglipron, highest approved dose, daily tablet (Foundayo) | [Foundayo label, Table 6](https://pi.lilly.com/us/foundayo-uspi.pdf), 72 weeks | −11.1% | −2.1% | These are group averages for brand medicines in their own trials; participants had differing responses and some stopped treatment. The current Wegovy label's Study 7 table reports a −2.4% placebo change with its specified analysis, while the OASIS 4 publication reports −2.2%; do not combine figures from different analyses. In particular, OASIS 1 studied oral semaglutide 50 mg: it should not be presented as the approved Wegovy tablet dose or as evidence for a compounded preparation. [Wegovy label, section 14.2](https://www.novo-pi.com/wegovy.pdf) ## Which weight-loss pills are FDA-approved? **Quick answer:** Long-term options include orlistat, phentermine/topiramate, naltrexone/bupropion, Wegovy tablets and, since April 1, 2026, Foundayo (orforglipron). Long-term weight-management options include orlistat, phentermine/topiramate, naltrexone/bupropion and Wegovy tablets. FDA also approved **Foundayo (orforglipron) on April 1, 2026**. It is therefore no longer accurate to describe Wegovy as the only oral GLP-1 option for obesity. Indications, precautions and approved ages depend on the product. [FDA: Foundayo approval](https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) [Contrave: prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b) [Adipex-P: prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf6e2aa5-e8e1-4478-93b9-47632a924482&version=22) [Wegovy: prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) The FDA-approved injectable options for long-term weight management include weekly semaglutide (Wegovy) and tirzepatide (Zepbound), and daily liraglutide (Saxenda). For more detail, see our guides to [FDA-approved weight-loss pills](/blog/fda-approved-weight-loss-pills/) and [how to choose a weight-loss medication](/blog/best-weight-loss-medication-for-you/). ## How do the pill and injection classes work? **Quick answer:** GLP-1 medicines come as pills and injections and act on appetite and glucose regulation; orlistat reduces fat absorption; other pills use different appetite pathways. Orlistat reduces fat absorption. Phentermine/topiramate and naltrexone/bupropion use other appetite-related pathways. GLP-1 receptor agonists influence appetite and glucose regulation. Phentermine alone is approved for short-term use; it should not be confused with a combination approved for long-term use. [Source: NIDDK: prescription weight-management medicines](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) ## How do daily routines differ between pills and injections? **Quick answer:** Injections are weekly or daily shots; pills are daily, and some, like Wegovy tablets, have strict fasting and water instructions while others do not. Route alone cannot rank medicines by effectiveness or tolerability. Administration rules also vary: semaglutide tablets have fasting instructions, but not every pill shares that schedule. A milligram dose of one product does not equal the same number for another. Do not convert oral and injectable doses yourself. | Product | Route and frequency | Routine to plan around | |---|---|---| | Wegovy injection; Zepbound | Weekly injection | One injection on a schedule, with training for the pen or device | | Saxenda | Daily injection | A daily injection | | Wegovy tablets | Daily tablet | Morning, on an empty stomach, with up to four ounces of water, then at least 30 minutes before food, drinks or other oral medicines | | Foundayo | Daily tablet | May be taken with or without food | | Orlistat (Xenical; alli) | Oral, linked to meals | Oily stools and urgency can affect your routine | Sources: [Wegovy label, section 2.1](https://www.novo-pi.com/wegovy.pdf), [Foundayo label, section 2](https://pi.lilly.com/us/foundayo-uspi.pdf), [NIDDK](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity). Neither tablet schedule is an instruction for a compounded oral preparation. ## Is compounded oral semaglutide an approved tablet? **Quick answer:** No. A compounded oral preparation is not Wegovy, Ozempic or Rybelsus and does not share their FDA approval or established clinical equivalence. A compounded oral preparation is not Wegovy, Ozempic or Rybelsus and does not have their approval. Approval of a molecule in one product does not transfer to another formulation, and branded-trial results do not establish results for a compounded preparation. [Source: FDA: unapproved GLP-1 medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) ## What should you ask your clinician about pills vs injections? **Quick answer:** Ask about the exact product's indication, your history and interactions, risks, daily routine, ongoing cost, follow-up, and how response will be assessed. Review the indication, history, interactions, risks, daily routine, ongoing cost and follow-up. Ask how response will be assessed and when the plan would change. [Review REMEVi’s oral semaglutide options](/oral-semaglutide/), which are compounded preparations distinct from approved tablets. For REMEVi's program charges, see [current pricing](/pricing/). ## Frequently asked questions ### Is Wegovy the only GLP-1 pill for obesity? No. FDA approved Foundayo (orforglipron) in April 2026. Each product has its own indications, instructions and risks. ### Is compounded oral semaglutide equivalent to an approved tablet? No. It does not share the approval or have established clinical equivalence to Wegovy, Ozempic or Rybelsus. ### Are pills safer than injections? The route alone does not establish safety. Each medicine has its own risks, interactions and administration instructions. Your health history and the exact product matter more than whether it is swallowed or injected. ### Can I switch from an injection to a pill at the same milligram dose? No. The same number of milligrams does not mean an equivalent dose across products or routes. Switching requires the prescriber's product-specific instructions; do not convert doses yourself. ## Sources linked in this article These are the external references linked in the article. A reference supports the statement where it appears; it is not an endorsement of REMEVi or a substitute for individual medical advice. - [OASIS 4](https://doi.org/10.1056/NEJMoa2500969) - [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/) - [SURMOUNT-1](https://pubmed.ncbi.nlm.nih.gov/35658024/) - [Foundayo label, Table 6](https://pi.lilly.com/us/foundayo-uspi.pdf) - [Wegovy label, section 14.2](https://www.novo-pi.com/wegovy.pdf) - [FDA: Foundayo approval](https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) - [Contrave: prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b) - [Adipex-P: prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf6e2aa5-e8e1-4478-93b9-47632a924482&version=22) - [Wegovy: prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) - [Source: NIDDK: prescription weight-management medicines](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) - [Source: FDA: unapproved GLP-1 medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) ## Related reading - [Rybelsus vs Ozempic: Pill vs Injection](/blog/rybelsus-vs-ozempic/) - [Weight-Loss Injections: Do You Need an Rx?](/blog/prescription-for-weight-loss-injections/) - [Types of Weight-Loss Injections Explained](/blog/types-of-weight-loss-injections/) ## About this article Published by REMEVi, a telehealth business offering paid treatment programs. REMEVi has a commercial interest in the services discussed here. Educational content supports informed conversations with a licensed clinician; it does not determine your eligibility or replace individual care.